Propranolol and toripalimab before surgery for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a beta-blocker (propranolol) and an immunotherapy drug (toripalimab) to standard chemotherapy can help shrink tumors before surgery in people with early-stage but advanced lung cancer. The goal is to improve surgery outcomes and reduce the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have stage II to IIIB non-small cell lung cancer that can be removed with surgery.
- You have not had any prior treatment for your lung cancer.
- You are healthy enough for surgery and daily activities (ECOG 0-1).
- You do not have certain genetic mutations in your tumor (EGFR, ALK, ROS1).
- You are able to take beta-blockers, which are commonly used for heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a beta-blocker (propranolol) to a combination of immunotherapy (sintilimab) and standard chemotherapy for people with advanced non-small cell lung cancer that hasn't been treated before. The goal is to see if this new triple treatment helps shrink tumors better than chemo-immunotherapy alone.
This trial tests whether the timing of immunotherapy infusion before surgery improves how well the tumor responds in people with stage II to III non-small cell lung cancer. It combines immunotherapy with standard chemotherapy to shrink the tumor before it is removed.
This trial tests whether giving an immunotherapy drug (toripalimab) before surgery can help people with a specific type of lung cancer (EGFR-mutated, PD-L1 positive) that can be removed. The goal is to see if it improves treatment results compared to surgery alone.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
This trial tests whether giving two immunotherapy drugs before surgery can help shrink non-small cell lung cancer and improve treatment success. The drugs are toripalimab and sacituzumab tirumotecan, which are given as intravenous infusions.
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.